XVII th International Myeloma Workshop 2019
The 17th International Myeloma Workshop under the auspices of the International Myeloma Society (IMS) is devoted to fostering scientific and clinical exchange on the latest breakthroughs in multiple myeloma and related plasma cell disorders. Over 3,000 participants are expected to attend the 17th IMW that will cover the latest genomic advances, insights into immune and microenvironmental dysregulation, new drug targets and agents, immunotherapeutic approaches including Car T-cell therapies, and breaking results from early and large randomized clinical trials.
The IMW 2019 will also feature a greatly expanded program of speakers and poster presenters selected from abstract submissions. Up to 40 young investigator award recipients will be selected from submitted abstracts for travel awards, and the chance to present their work and be honored at the Opening Ceremonies at the Boston Museum of Science. A black-tie event honoring IMS award recipients and workshop attendees will be held at the world-renowned Boston Museum of Fine Arts for the Closing Ceremonies. The 17th IMW will also feature a dedicated nursing symposium covering management and treatment of multiple myeloma. Nurses and allied health professionals are invited to attend and submit abstracts. Please join us for this defining conference on myeloma and the related plasma cells disorders.
This course is designed for MD, RN, NP, PA, Ph.D. The Workshop is to educate the scientist, medical professional, clinician, researcher, and patient advocate to reach understanding on the following goals and directions for the specified plasma cell myeloma- Multiple myeloma (MM).
• Recognize the progress on genomic landscape and evolution of multiple myeloma and the surrounding genetic environment
• Recognize diagnostic and treatment implications with antibody treatment approaches for multiple myeloma
• Recognize role of predictive genomics and precursor conditions in multiple myeloma in treatment choice.
• Utilize recent clinico-pathological and molecular findings to distinguish multiple myeloma from overlapping plasma cell disorders.
• Recognize multiple myeloma diagnostics on a molecular and testing level, and the current review of the NCCN guidelines
• Recognize genetic predispositions to multiple myeloma, and implications for clinical therapy including use of antibody treatment and immunotherapeutic approaches.
• Recognize application and limitations of current neoplastic therapy for frontline and salvage therapy of multiple myeloma including transplantation.
In support of improving patient care, this activity has been planned and implemented by Mayo Clinic College of Medicine and Science and International Myeloma Society. Mayo Clinic College of Medicine and Science is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 30.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The credit breakdown per day is as follows:
Thursday - 7.75
Friday Plenary - 10
Friday Ballroom - 6
Saturday Plenary - 9
Saturday Ballroom - 6
Sunday - 3.5
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 5.75 ANCC nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Nursing credit is only available for the Nursing Symposium.
For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.
- 30.25 AMA PRA Category 1 Credit™
- 5.75 ANCC
- 30.25 Attendance